Generation and functional characterisation of dendritic cells from patients with pancreatic carcinoma with special regard to clinical applicability

Cancer Immunology Immunotherapy

Volumn 49, Issue 10, 2000, Pages 544-550

  Piemonti, Lorenzo ^a   Monti, Paolo ^a   Zerbi, Alessandro ^a   Balzano, Gianpaolo ^a   Allavena, Paola ^b   Di Carlo, Valerio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Adenocarcinoma; Dendritic cells; Human; Pancreas

Indexed keywords

GLYCOPROTEIN GP 39; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4;

ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CELL CULTURE; CELL FUNCTION; CELL STIMULATION; CLINICAL ARTICLE; DENDRITIC CELL; HUMAN; HUMAN CELL; PANCREAS CARCINOMA; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0033653518     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620000149     Document Type: Article

References (44)

1. Interleukin-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages
2. The dendritic cell system and antitumor immunity in vivo
3. Dendritic cells and the control of immunity
4. Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor specific immunity
5. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood
6. From defined human tumor antigens to effective immunization?
7. Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage-colony-stimulating factor
8. Human dendritic cell response to lipopolysaccharide and CD40 ligation are differentially regulated by interleukin-10
9. The current management of carcinoma of the head of the pancreas
10. Recent advances in the study of dendritic cells and follicular dendritic cells
11. Peptide pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity
12. Differentiation of human dendritic cells from monocytes in vitro
13. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity
14. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells
15. Identification of a peptide recognized by five melanoma-specific human cyotoxic T cell lines
16. Effect of interleukin-10 dendritic cell maturation and function
17. Gene transfer as cancer therapy
18. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo
19. Increased interleukin-10 serum levels in patients with solid tumours
20. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
21. Radical oncologic surgery affects the circulatory levels of IL-10
22. Dendritic cells hold promise for immunotherapy
23. Vaccination with mutant ras peptides and induction of t-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation
24. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells
25. Dendritic cells: Unique leukocyte populations which control the primary immune response
26. + T cells
27. Development and characterization of a cytokinesecreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials
28. National patterns of care for pancreatic cancer
29. Prognosis in pancreatic cancer
30. In vivo priming of two distinct antitumor effector population: The role of MHC class I expression
31. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma
32. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
33. Analysis of TCR usage in human tumors: A new tool for assessing tumor-specific immune response
34. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes
35. Human pancreatic cancer cells (mpanc-96) recognized by autologous tumor-infiltrating lymphocytes after in vitro as well as in vivo tumor expansion
36. IL-13 supports differentiation of dendritic cells from circulating precursors in concert with GM-CSF
37. Molecular mechanisms used by tumors to escape immune recognition: Immunogenetherapy and the cell biology of major histocompatibility complex class I
38. Generation of mature dendritic cells from human blood an improved method with special regard to clinical applicability
39. Immune response against tumors
40. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α
41. Dendritic cells as adjuvants for immune-mediated resistance to tumors
42. Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary and pancreas and other tumors
43. The dendritic cell system and its role in immunogenicity
44. Human cytotoxic lymphocytes reactive with pancreatic adenocarcinoma cells